BiomX
Sector: Healthcare & Life Sciences
About BiomX
Developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Products
BOLT Platofrm, BX004 (CF Phage); BX005 (Atopic Dermatitis Phage)
BiomX develops phage cocktails (or combinations) that target and kill specific pathogenic bacteria. Phage cocktails, which are optimized through algorithms and experimental validation (in-vitro and in-vivo), contain multiple natural and/or engineered phage. The phage are selected to have complementary functions such as wide target bacterial host range and the ability to avoid the development of bacterial resistance, among other characteristics. Bacteriophage, or phage, are viruses that target bacteria and are considered inert to mammalian cells. Phage are natural predators of bacteria and are found wherever bacteria exist. Phage are specific to particular bacterial species or strains, targeting and killing them without disrupting other neighboring, potentially beneficial, bacteria. Phages target and rapidly kill their bacterial hosts by amplifying inside these bacteria and consequently releasing new phage by bursting through the host cell membrane into the surrounding environment. These newly released phage infect and kill additional nearby bacterial cells in a reiterative process that leads to elimination of the target bacteria The BOLT platform (“BacteriOphage Lead to Treatment”) is comprised of proprietary computational tools, automated screening, synthetic engineering capabilities and various validation assays aimed at developing natural or engineered phage cocktails that target a particular pathogenic bacteria. We apply the platform to develop phage cocktails directed through two development paths as outlined below. Personalized Phage Treatment Tailored to target strains of a specific patient within 6-8 weeks. Running such production suites in parallel for multiple patients allows to conduct a clinical Personalized proof of concept within 12-18 months from project initiation. Optimized Phage Therapy Optimized for bacterial host range, resistance, other factors, to target a broad patient population as a go to market product.